FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186457582> ?p ?o ?g. }

• W3186457582 endingPage "1351" @default.
• W3186457582 startingPage "1342" @default.
• W3186457582 abstract "Prostate cancer oligometastatic disease can be treated using stereotactic body radiotherapy (SBRT) in order to postpone start of systemic treatments such as androgen deprivation therapy (ADT). 68Ga-PSMA-PET/CT imaging allows for diagnosis of oligometastases at lower PSA values. We analysed a cohort of patients with prostate cancer lymph node oligometastases detected on PSMA-PET/CT.Ninety patients with metachronous oligometastatic prostate cancer received SBRT for 1-3 lymph node metastases diagnosed on 68Ga-PSMA-PET/CT. The primary end point was progression free survival (PFS), with disease progression defined as occurrence of either target lesion progression, new metastatic lesion or biochemical progression. Secondary outcomes were biochemical PFS (BPFS), ADT-free survival (ADT-FS), toxicity and quality of life (QoL). Baseline patient characteristics were tested for association with PFS and a preliminary risk score was created.Median follow-up was 21 months (interquartile range 10-31 months). Median PFS and BPFS were 16 and 21 months, respectively. Median ADT-FS was not reached (73% (95%-CI 62-86%) at 24 months). In multivariable analysis, younger age, higher PSA prior to SBRT and extrapelvic location were associated with shorter PFS. Grade 1 fatigue was the most predominant acute toxicity (34%). Highest grade toxicity was grade 2 for acute and late events. QoL analysis showed mild, transient increase in fatigue at 1-4 weeks after SBRT.A median PFS of 16 months was attained after SBRT for patients with PSMA-PET positive oligometastatic lymph nodes from prostate cancer. Higher pre-SBRT PSA, younger age and extrapelvic location were found to be predictors of shorter PFS." @default.
• W3186457582 created "2021-08-02" @default.
• W3186457582 creator A5008140267 @default.
• W3186457582 creator A5021970576 @default.
• W3186457582 creator A5027089510 @default.
• W3186457582 creator A5039957828 @default.
• W3186457582 creator A5041935653 @default.
• W3186457582 creator A5042729624 @default.
• W3186457582 creator A5079018420 @default.
• W3186457582 date "2021-07-29" @default.
• W3186457582 modified "2023-10-14" @default.
• W3186457582 title "Progression-free survival in patients with ⁶⁸Ga-PSMA-PET-directed SBRT for lymph node oligometastases" @default.
• W3186457582 cites W1987092451 @default.
• W3186457582 cites W1990166011 @default.
• W3186457582 cites W2003239266 @default.
• W3186457582 cites W2030521036 @default.
• W3186457582 cites W2095128112 @default.
• W3186457582 cites W2115843235 @default.
• W3186457582 cites W2129925362 @default.
• W3186457582 cites W2167571044 @default.
• W3186457582 cites W2218810808 @default.
• W3186457582 cites W2574121943 @default.
• W3186457582 cites W2604258833 @default.
• W3186457582 cites W2775321189 @default.
• W3186457582 cites W2782176193 @default.
• W3186457582 cites W2801911503 @default.
• W3186457582 cites W2802703095 @default.
• W3186457582 cites W2805432229 @default.
• W3186457582 cites W2906456065 @default.
• W3186457582 cites W2908832015 @default.
• W3186457582 cites W2913811067 @default.
• W3186457582 cites W2918645403 @default.
• W3186457582 cites W2964111579 @default.
• W3186457582 cites W2967730564 @default.
• W3186457582 cites W2972275304 @default.
• W3186457582 cites W2972533565 @default.
• W3186457582 cites W2975187676 @default.
• W3186457582 cites W2977107258 @default.
• W3186457582 cites W2991630976 @default.
• W3186457582 cites W2997721110 @default.
• W3186457582 cites W3013251573 @default.
• W3186457582 cites W3024645857 @default.
• W3186457582 cites W3025293463 @default.
• W3186457582 cites W3032651552 @default.
• W3186457582 cites W3038750967 @default.
• W3186457582 cites W3039778549 @default.
• W3186457582 cites W3047110054 @default.
• W3186457582 cites W3087097164 @default.
• W3186457582 cites W3093631491 @default.
• W3186457582 cites W3104612125 @default.
• W3186457582 cites W3125743225 @default.
• W3186457582 cites W4233026002 @default.
• W3186457582 doi "https://doi.org/10.1080/0284186x.2021.1955970" @default.
• W3186457582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34323648" @default.
• W3186457582 hasPublicationYear "2021" @default.
• W3186457582 type Work @default.
• W3186457582 sameAs 3186457582 @default.
• W3186457582 citedByCount "7" @default.
• W3186457582 countsByYear W31864575822022 @default.
• W3186457582 countsByYear W31864575822023 @default.
• W3186457582 crossrefType "journal-article" @default.
• W3186457582 hasAuthorship W3186457582A5008140267 @default.
• W3186457582 hasAuthorship W3186457582A5021970576 @default.
• W3186457582 hasAuthorship W3186457582A5027089510 @default.
• W3186457582 hasAuthorship W3186457582A5039957828 @default.
• W3186457582 hasAuthorship W3186457582A5041935653 @default.
• W3186457582 hasAuthorship W3186457582A5042729624 @default.
• W3186457582 hasAuthorship W3186457582A5079018420 @default.
• W3186457582 hasBestOaLocation W31864575821 @default.
• W3186457582 hasConcept C119060515 @default.
• W3186457582 hasConcept C121608353 @default.
• W3186457582 hasConcept C126322002 @default.
• W3186457582 hasConcept C126838900 @default.
• W3186457582 hasConcept C126894567 @default.
• W3186457582 hasConcept C143998085 @default.
• W3186457582 hasConcept C2776694085 @default.
• W3186457582 hasConcept C2777008409 @default.
• W3186457582 hasConcept C2777899217 @default.
• W3186457582 hasConcept C2779466945 @default.
• W3186457582 hasConcept C2780192828 @default.
• W3186457582 hasConcept C2780739268 @default.
• W3186457582 hasConcept C2780849966 @default.
• W3186457582 hasConcept C71924100 @default.
• W3186457582 hasConcept C72563966 @default.
• W3186457582 hasConceptScore W3186457582C119060515 @default.
• W3186457582 hasConceptScore W3186457582C121608353 @default.
• W3186457582 hasConceptScore W3186457582C126322002 @default.
• W3186457582 hasConceptScore W3186457582C126838900 @default.
• W3186457582 hasConceptScore W3186457582C126894567 @default.
• W3186457582 hasConceptScore W3186457582C143998085 @default.
• W3186457582 hasConceptScore W3186457582C2776694085 @default.
• W3186457582 hasConceptScore W3186457582C2777008409 @default.
• W3186457582 hasConceptScore W3186457582C2777899217 @default.
• W3186457582 hasConceptScore W3186457582C2779466945 @default.
• W3186457582 hasConceptScore W3186457582C2780192828 @default.
• W3186457582 hasConceptScore W3186457582C2780739268 @default.
• W3186457582 hasConceptScore W3186457582C2780849966 @default.
• W3186457582 hasConceptScore W3186457582C71924100 @default.

• next